Changing the trajectory of mental health care ...
One Mind at a Time
About Us
Committed to developing a new generation of CNS medicines that go beyond the current standard of care
WorldPharma is developing an innovative pipeline of Central Nervous System (CNS) medications with the potential to establish new standards of care in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of people in the U.S. and around the world.
Our Vision
Striving for a world no longer gripped by anxiety and depression
WorldPharma’s core goal is to radically improve mental health and well-being worldwide. In developing safe and effective treatments, we aim to improve mental health care with better outcomes for patients, caregivers, advocates and communities.
Large Unmet Mental Health Care Needs in Anxiety and Depression
1. Kantar Health. Nov 2021. National Health and Wellness Survey (NHWS), 2021. [US]. Malvern, PA. | 2. Substance Abuse and Mental Health Services Administration, 2020 | 3. World Health Organization
Pipeline
WorldPharma Products in Development
For Anxiety Disorders
Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray designed with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with currently prescribed anti-anxiety products.
For Depression
Itruvone is a rapid-onset investigational pherine nasal spray designed for potential stand-alone treatment for major depressive disorder and other neuropsychiatric indications involving depression.
For Improvement of Cognition
PH15 is an investigational pherine designed as a potential new treatment for many disorders that lead to sleep deprivation and ensuing fatigue and cognitive impairment.
For Menopausal Hot Flashes and Migraine
Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray designed with potential to treat multiple anxiety disorders without the side effects and safety concerns associated with currently prescribed anti-anxiety products.
For Appetite-related Disorders
PH284 is an investigational pherine with potential to treat appetite related disorders such as Cachexia (Wasting Syndrome), a serious but under recognized consequence of many chronic diseases and advanced cancer.
For CNS Diseases & Disorders
AV-101 (4-Cl-KYN) is an investigational oral prodrug of 7-Cl-KYNA, a full antagonist of the glycine site of the NMDA receptor, with potential to treat multiple CNS diseases and disorders.
Our Lab Certification
Certification of Laboratories that Analyze Drinking Water Samples to Ensure Compliance with Regulations
Latest News
Technology
The Challenges of Defining, Understanding, and Addressing Long COVID
The scientific community wants to come to an agreement about how to diagnosis or treat long COVID. First they need to agree on what it is.
Articles
Talking to Inanimate Objects Made Me a Better Designer
Some people think obesity is simply caused by unhealthy eating habits and not exercising enough. But, in fact, the scientific and medical community defines obesity as a complex, multifactoral chronic disease.
Articles
How to Dispose of Unused Medicine Responsibly to Protect the Environment
Would it surprise you to learn that taking prescription medication is part of the daily routine for an estimated 60% of adults in the United States?